This AI Trade Machine Made 1,729%* (With 89% Wins)

This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work?

David R. Ebsworth net worth and biography

David Ebsworth Biography and Net Worth

Director of Verona Pharma

Dr Ebsworth has significant experience in leadership and management of pharma and biotech companies internationally. Dr Ebsworth currently serves on the boards of Sartorius and Synlab. From October 2009 to August 2014, Dr Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. In 2012, Dr Ebsworth was also named as Chief Executive Officer of Galenica and as Chairman of Galenica’s Executive Committee, positions he held until August 2014. In his earlier career, Dr Ebsworth worked with Bayer for over 19 years, heading the Canadian, North American and global pharmaceutical business. Dr Ebsworth received a PhD in industrial relations from the University of Surrey.

What is David R. Ebsworth's net worth?: The estimated net worth of David R. Ebsworth is at least $13.07 million as of November 6th, 2023. Dr. Ebsworth owns 844,643 shares of Verona Pharma stock worth more than $13,066,627 as of April 28th. This net worth evaluation does not reflect any other investments that Dr. Ebsworth may own. Learn More about David R. Ebsworth's net worth.
How do I contact David R. Ebsworth?: The corporate mailing address for Dr. Ebsworth and other Verona Pharma executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on David R. Ebsworth's contact information.
Has David R. Ebsworth been buying or selling shares of Verona Pharma?: David R. Ebsworth has not been actively trading shares of Verona Pharma in the last ninety days. Most recently, on Monday, November 6th, David R. Ebsworth bought 160,000 shares of Verona Pharma stock. The stock was acquired at an average cost of $1.98 per share, with a total value of $316,800.00. Following the completion of the transaction, the director now directly owns 844,643 shares of the company's stock, valued at $1,672,393.14. Learn More on David R. Ebsworth's trading history.
Who are Verona Pharma's active insiders?: Verona Pharma's insider roster includes Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma's active insiders.
Are insiders buying or selling shares of Verona Pharma?: In the last year, Verona Pharma insiders bought shares 2 times. They purchased a total of 193,736 shares worth more than $378,874.24. In the last year, insiders at the sold shares 19 times. They sold a total of 2,164,281 shares worth more than $13,411,301.36. The most recent insider tranaction occured on November, 20th when Director Martin Edwards bought 33,736 shares worth more than $62,074.24. Insiders at Verona Pharma own 4.8% of the company. Learn More about insider trades at Verona Pharma.
Information on this page was last updated on 11/20/2023.

David R. Ebsworth Insider Trading History at Verona Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/6/2023	Buy	160,000	$1.98	$316,800.00	844,643

David R. Ebsworth Buying and Selling Activity at Verona Pharma

Verona Pharma Company Overview

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Today's Range

Now: $15.47

$15.25

$15.60

50 Day Range

MA: $16.34

$15.24

$18.19

2 Week Range

Now: $15.47

$11.83

$23.81

Volume

260,511 shs

Average Volume

413,627 shs

Market Capitalization

$1.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

This AI Trade Machine Made 1,729%* (With 89% Wins)

From Prosper Trading Academy | Ad